---
pmid: '18606987'
title: HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox
  regulation.
authors:
- Parmigiani RB
- Xu WS
- Venta-Perez G
- Erdjument-Bromage H
- Yaneva M
- Tempst P
- Marks PA
journal: Proc Natl Acad Sci U S A
year: '2008'
full_text_available: false
pmcid: PMC2443817
doi: 10.1073/pnas.0803749105
---

# HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation.
**Authors:** Parmigiani RB, Xu WS, Venta-Perez G, Erdjument-Bromage H, Yaneva M, Tempst P, Marks PA
**Journal:** Proc Natl Acad Sci U S A (2008)
**DOI:** [10.1073/pnas.0803749105](https://doi.org/10.1073/pnas.0803749105)
**PMC:** [PMC2443817](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2443817/)

## Abstract

1. Proc Natl Acad Sci U S A. 2008 Jul 15;105(28):9633-8. doi: 
10.1073/pnas.0803749105. Epub 2008 Jul 7.

HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox 
regulation.

Parmigiani RB(1), Xu WS, Venta-Perez G, Erdjument-Bromage H, Yaneva M, Tempst P, 
Marks PA.

Author information:
(1)Cell Biology and Molecular Biology Programs, Memorial Sloan-Kettering Cancer 
Center, 1275 York Avenue, New York, NY 10065, USA.

Eighteen histone deacetylases (HDACs) are present in humans, categorized into 
two groups: zinc-dependent enzymes (HDAC1-11) and NAD(+)-dependent enzymes 
(sirtuins 1-7). Among zinc-dependent HDACs, HDAC6 is unique. It has a 
cytoplasmic localization, two catalytic sites, a ubiquitin-binding site, and it 
selectively deacetylases alpha-tubulin and Hsp90. Here, we report the discovery 
that the redox regulatory proteins, peroxiredoxin (Prx) I and Prx II are 
specific targets of HDAC6. Prx are antioxidants enzymes whose main function is 
H(2)O(2) reduction. Prx are elevated in many cancers and neurodegenerative 
diseases. The acetylated form of Prx accumulates in the absence of an active 
HDAC6. Acetylation of Prx increases its reducing activity, its resistance to 
superoxidation, and its resistance to transition to high-molecular-mass 
complexes. Thus, HDAC6 and Prx are targets for modulating intracellular redox 
status in therapeutic strategies for disorders as disparate as cancers and 
neurodegenerative diseases.

DOI: 10.1073/pnas.0803749105
PMCID: PMC2443817
PMID: 18606987 [Indexed for MEDLINE]

Conflict of interest statement: Conflict of interest statement: Memorial 
Sloanâ€“Kettering Cancer Center and Columbia jointly hold patents on SAHA and 
related compounds that were exclusively licensed to ATON Pharma, acquired by 
Merck in April 2004. P.A.M. was a founder of ATON and has a financial interest 
in the further development of SAHA (vorinostat) by Merck.
